From thymus extracts to synthetic thymomimetics
I. V. Nesterova, L. V. Lomtatidze, G. A. Chudilova, S. V. Kovaleva, V. N. Chapurina, S. N. Pikturno · 2026 · Adaptive Medical Immunology and Public Health Issues. 2026;2(1):6–19.
Reported findings and study design
Narrative findings; numerical extraction incomplete
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thymomimetic research | The authors summarize evidence from different thymic compounds and discuss changes in neutrophil phenotype and function in studies of Imunofan. |
Secondary synthesis. No new clinical cohort or pooled effect estimate.
Source for these results ↗ · Reviewed 2026-11-10
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Cell markers, laboratory findings and outcomes from combination care answer different questions. The review does not validate efficacy across thymic peptides.
Source access
Original Russian review and cited evidence types checked. The review does not present a new controlled trial or pooled estimate.
Source reviewed 2026-11-10.
Source type: Narrative review
Citation and original source
Original source: I. V. Nesterova, L. V. Lomtatidze, G. A. Chudilova, S. V. Kovaleva, V. N. Chapurina, S. N. Pikturno. From thymus extracts to synthetic thymomimetics Adaptive Medical Immunology and Public Health Issues. 2026;2(1):6–19. 2026.
Molekul research summary: https://molekul.io/research/nesterova-thymic-peptide-review-2026. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymalin
Thymus-derived peptide mixture with historical Russian studies in autoimmune cytopenias and thyroiditis, alongside other treatments. It is distinct from synthetic Thymogen and Thymodepressin.
Thymogen
EW is discussed in the thymus-derived research program. Thymalin extract outcomes cannot be assigned to this defined peptide.
Vilon
Defined Lys–Glu (KE) dipeptide with historical adjunct-treatment reports in type 1 diabetes and separate laboratory research. Immune and coagulation-marker findings do not establish autoimmune disease modification.
Imunofan
A synthetic RDKVYR hexapeptide with cell, animal and human wound-related research. Historical Thymohexin names have conflicting sequence order.